A pooled analysis of two phase 3 ENHANCE trials evaluated whether the inhaled dual phosphodiesterase 3 and 4 inhibitor antifeminine reduces chronic obstructive pulmonary disease exacerbation frequency and...
A nationwide Belgian cohort study found that biologic therapy targeting interleukin (IL) 5 reduced moderate and severe exacerbations among adults with severe eosinophilic asthma, including those with...
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality, but it’s also highly manageable with early recognition, evidence-based treatment, and coordinated care. This guide...
A randomized trial demonstrated that telemedicine follow-up after COPD exacerbation improved symptom scores and inhaler technique compared with standard face-to-face care, supporting its role as a safe and...
A randomized trial in moderate chronic obstructive pulmonary disease demonstrated that chest mobility exercises led to greater improvements in lung function and functional capacity compared with...
A multicenter retrospective cohort study across the Yale-New Haven Health System found that embedding a 2-part electronic health record–based care pathway for patients hospitalized with chronic obstructive...
Patients with chronic obstructive pulmonary disease who recovered from COVID-19 had nearly double the risk of long-term mortality compared with matched controls, with the highest risk observed in severe...
The results from a recent phase 3 trial indicate that mepolizumab significantly reduces moderate and severe exacerbations in patients with eosinophilic chronic obstructive pulmonary disease.
Recent studies show distinct metabolic disruptions in children with multisystem inflammatory syndrome in children, plaque progression in adults post–COVID-19, and surprising pneumococcal risk patterns.
...
A recent randomized clinical trial demonstrated that a nurse and social worker-led palliative telecare intervention improved quality of life, mental health, and disease-specific outcomes for patients with...
